PDGFRB and cancer: Notably, this included TGF-β (TGFB1, TGFB3), drivers of adenosine-mediated immune suppression (NT5E (CD73), ENTPD1 (CD39)), Wnt pathway ligands (WNT7A, WNT4), IL10 and drivers/markers of cancer-associated fibroblast activation (INHBA, WNT7A, TGFB1, FAP, PDGFRA, PDGFRB) [81–83] (Additional file 2: Table S1).